MedPath

Swallowing therapy for patients with head neck cancer treated with chemoradiation therapy: A Randomized Control Trial

Phase 2
Conditions
Health Condition 1: C103- Malignant neoplasm of posterior wall of oropharynx
Registration Number
CTRI/2024/07/071024
Lead Sponsor
Sri Ramachandra Hospital and Medical Center
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

It is proposed to enrol a cohort of HNC adults= 18 years of age, both sexes, newly diagnosed carcinoma of the oropharynx, hypopharynx, or supraglottic larynx with squamous cell carcinoma histology in stages T2-T4, N+, and M0. Patients who will have to be scheduled for chemotherapy with IMRT with a dose of 66 Gy in 33 fractions of the gross tumor volume and involved nodal disease over 6.5 weeks with chemotherapy and are willing to participate will be included.

Exclusion Criteria

Patients other than the oropharynx, hypopharynx, and supraglottic larynx or with distant metastasis will be excluded from the study. Also, patients with a history of recurrence, head and neck surgery, or surgery scheduled due to HNC or co-morbid neurological deficits or diseases affecting swallowing function will be excluded from the study.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath